Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Rhythm Biosciences Ltd. ( (AU:RHY) ).
Rhythm Biosciences Ltd has announced that its ColoSTAT® kits have achieved breakthrough clinical performance across all stages of colorectal cancer, from I to IV. The kits have transitioned to the final production validation stage, with high-quality kits received for internal testing. The consistent diagnostic performance across all cancer stages meets clinical requirements for use in symptomatic patient testing, with commercialization steps underway. The company plans to submit the ColoSTAT® for inclusion in its ISO15189 laboratory test portfolio, with a commercial launch expected later in 2025, pending regulatory approval.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd (ASX: RHY) is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden by partnering with global entities for the commercialization and distribution of its solutions.
Average Trading Volume: 316,853
Technical Sentiment Signal: Sell
Current Market Cap: A$17.42M
For detailed information about RHY stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money